1. Clinical & Scientific Overview
Itraconazole & Voriconazole (TIP-MED-000161, Reference Code [8.33]) is classified under
Antimicrobials — Systemic Antifungal Agents (Ch 08) as a Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inhibitors (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.33], p. 109): Itraconazole: Canditral (Glenmark), Sporanox (J&J), Itrasys, SUBA-Itraconazole: Itratuf / Lozanoc (50/65/130 mg). Voriconazole: Vorier (Zydus), Vfend (Pfizer), Voritek (Cipla) — Strengths & Dosage Forms: Itraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventional 100 mg!). Voriconazole Tablets: 50 mg, 200 mg; IV Vial: 200 mg
Itraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventional 100 mg!). Voriconazole Tablets: 50 mg, 200 mg; IV Vial: 200 mg
3. Mechanism of Action & Pharmacodynamics
Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inhibitors (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Systemic Antifungal Agents (Ch 08): clinical efficacy is mediated via Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inhibitors (Schedule H | NLEM 2022) for Itraconazole: Extensive/recalcitrant dermatophytosis (tinea corporis/cruris/onychomycosis), sporotrichosis, histoplasmosis, ABPA. Voriconazole: First-line drug of choice for Invasive Aspergillosis, Candida krusei/glabrata, and Fusarium infections.
4. Therapeutic Indications & Evidence-Supported Uses
- Itraconazole: Extensive/recalcitrant dermatophytosis (tinea corporis/cruris/onychomycosis), sporotrichosis, histoplasmosis, ABPA
- Voriconazole: First-line drug of choice for Invasive Aspergillosis, Candida krusei/glabrata, and Fusarium infections
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Itraconazole (Conventional): Tinea: 100–200 mg PO OD–BD for 2–4 weeks; Onychomycosis: 200 mg BD x 7d/month for 2–3 pulses (SUBA: 65–130 mg OD–BD). Voriconazole (Adults >=40 kg): Load 400 mg PO (or 6 mg/kg IV) q12h x 2 doses on Day 1, then Maintenance 200 mg PO (or 4 mg/kg IV) q12h
Administration & Meal Timing: OPPOSITE FOOD & ACID RULES: (1) Conventional Itraconazole (100/200 mg) MUST BE TAKEN IMMEDIATELY AFTER A FULL MEAL AND REQUIRES GASTRIC ACID (SUBA-Itraconazole does not require acid/food). (2) Oral Voriconazole MUST BE TAKEN ON AN EMPTY STOMACH (1h before or 2h after a meal)! | Morning & Evening (12-hourly BD) or OD (Itraconazole)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!
Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!
Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!
7. Contraindications, Precautions & High-Risk Warnings
- BOXED WARNINGS: (1) Itraconazole has negative inotropic effects and is CONTRAINDICATED in Heart Failure (HFrEF) and pregnancy. (2) Both are among the MOST POTENT CYP3A4 INHIBITORS in medicine — contraindicated with Simvastatin, Lovastatin, Atorvastatin (>20 mg), Ticagrelor, Ivabradine, Ranolazine, Eplerenone, Dabigatran, Rivaroxaban, Colchicine, Domperidone, Quetiapine, Midazolam, and Ergotamine!
Key Clinical Precautions: Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!
8. Adverse Effects Profile
- Itraconazole: Nausea, abdominal pain, headache, ankle oedema, hypertension, hypokalaemia. Voriconazole: Transient visual disturbances (30% — blurred vision, altered colour perception within 30m of dose, lasting ~30m!), photosensitivity rash, hallucinations, transaminitis
- Acute Congestive Heart Failure (Itraconazole), severe hepatotoxicity/acute liver failure (both), QTc prolongation / Torsades de Pointes, visual hallucinations & encephalopathy, peripheral neuropathy
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- PPIs, H2RAs, and Antacids reduce Conventional Itraconazole absorption by 50–70%! Rifampicin, Carbamazepine, and Phenytoin reduce Itraconazole & Voriconazole levels to zero (contraindicated!)
- Both markedly increase Tacrolimus, Cyclosporine, Sirolimus, Warfarin, Sulfonylureas, Digoxin, CCBs, and Budesonide/Fluticasone inhalers!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: CRITICAL COUNTER DISTINCTIONS: (1) Verify whether Itraconazole is Conventional 100/200 mg (must take right after a full meal; avoid PPIs!) or SUBA 65/130 mg; (2) Pause Atorvastatin/Simvastatin during Itraconazole therapy; (3) For Voriconazole (Vorier): take on an empty stomach 1h before food, do not drive at night if vision blurs, and wear strict sun protection
- Meal & Clock Timing Instruction: OPPOSITE FOOD & ACID RULES: (1) Conventional Itraconazole (100/200 mg) MUST BE TAKEN IMMEDIATELY AFTER A FULL MEAL AND REQUIRES GASTRIC ACID (SUBA-Itraconazole does not require acid/food). (2) Oral Voriconazole MUST BE TAKEN ON AN EMPTY STOMACH (1h before or 2h after a meal)! (Morning & Evening (12-hourly BD) or OD (Itraconazole))
- Missed Dose Protocol: Take as soon as remembered unless within 4h of next dose
- Geriatric Dispensing Pearl: Screen older adults for heart failure, CCBs, Statins, and anticoagulants before dispensing Itraconazole
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Itraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventional 100 mg!). Voriconazole Tablets: 50 mg, 200 mg; IV Vial: 200 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.33] (p. 109)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.34] Terbinafine Hydrochloride & Griseofulvin — Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inh
- [8.33]-C76 Voriconazole — Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifu
- [8.34]-C77 Griseofulvin — Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inh
- [8.13] Fluconazole — Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Ste